

# CITATION REPORT

List of articles citing

## The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

DOI: 10.1016/j.chembiol.2017.09.009  
Cell Chemical Biology, 2018, 25, 67-77.e3.

**Source:** <https://exaly.com/paper-pdf/69722492/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
341	Targeting the C481S Ibrutinib-Resistance Mutation in Brutons Tyrosine Kinase Using PROTAC-Mediated Degradation.		
340	Purification and characterization of two forms of a high-molecular-weight cysteine proteinase (porphypain) from <i>Porphyromonas gingivalis</i> . <b>1994</b> , 176, 4549-57		60
339	PROTACs: An Emerging Targeting Technique for Protein Degradation in Drug Discovery. <b>2018</b> , 40, e1700247		99
338	Try Me: Promiscuous Inhibitors Still Allow for Selective Targeted Protein Degradation. <i>Cell Chemical Biology</i> , <b>2018</b> , 25, 4-6	8.2	4
337	Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. <b>2018</b> , 13, 553-560		78
336	Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). <b>2018</b> , 151, 304-314		114
335	Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead. <i>Cell Chemical Biology</i> , <b>2018</b> , 25, 78-87.e5	8.2	339
334	Enhancing Antiproliferative Activity and Selectivity of a FLT-3 Inhibitor by Proteolysis Targeting Chimera Conversion. <b>2018</b> , 140, 16428-16432		88
333	Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. <b>2018</b> , 36, 553-562		138
332	Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase. <b>2018</b> , 8, 13549		35
331	[Development of Protein Knockdown Technology as Emerging Drug Discovery Strategy]. <b>2018</b> , 138, 1135-11434		
330	Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation. <b>2018</b> , 57, 3564-3575		169
329	Androgen receptor degradation by the proteolysis-targeting chimera ARCC-4 outperforms enzalutamide in cellular models of prostate cancer drug resistance. <b>2018</b> , 1, 100		157
328	When Kinases Meet PROTACs. <b>2018</b> , 36, 971-977		18
327	Homo-PROTACs for the Chemical Knockdown of Cereblon. <b>2018</b> , 13, 2771-2782		68
326	Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action. <b>2018</b> , 13, 2758-2770		123
325	Proteolysis Targeting Chimeras for the Selective Degradation of Mcl-1/Bcl-2 Derived from Nonselective Target Binding Ligands. <b>2019</b> , 62, 8152-8163		53

324	Small molecule degraders of the hepatitis C virus protease reduce susceptibility to resistance mutations. <b>2019</b> , 10, 3468	62
323	Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-Mediated Targeted Protein Degradation. <b>2019</b> , 79, 4744-4753	87
322	Regulatory Molecules and Corresponding Processes of BCR-ABL Protein Degradation. <b>2019</b> , 10, 2488-2500	4
321	Potent and Preferential Degradation of CDK6 via Proteolysis Targeting Chimera Degraders. <b>2019</b> , 62, 7575-7582	81
320	Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity. <b>2019</b> , 62, 7042-7057	77
319	Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality. <b>2019</b> , 10, 1592-1602	21
318	A Potent and Selective Small-Molecule Degradator of STAT3 Achieves Complete Tumor Regression In Vivo. <b>2019</b> , 36, 498-511.e17	181
317	Targeted protein degradation: expanding the toolbox. <b>2019</b> , 18, 949-963	276
316	Proteasome-Independent Protein Knockdown by Small-Molecule Inhibitor for the Undruggable Lung Adenocarcinoma. <b>2019</b> , 141, 18492-18499	11
315	Trajectory Planning and Tracking Control of Vehicle Obstacle Avoidance based on Optimization Control. <b>2019</b> ,	1
314	Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. <b>2019</b> , 10, 131	188
313	Targeting transcription factors in cancer - from undruggable to reality. <b>2019</b> , 19, 611-624	208
312	Discovery of SIAIS178 as an Effective BCR-ABL Degradator by Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. <b>2019</b> , 62, 9281-9298	47
311	PROTACs- a game-changing technology. <b>2019</b> , 14, 1255-1268	63
310	Reversible Spatiotemporal Control of Induced Protein Degradation by Bistable PhotoPROTACs. <b>2019</b> , 5, 1682-1690	87
309	Induced degradation of protein kinases by bifunctional small molecules: a next-generation strategy. <b>2019</b> , 14, 1237-1253	10
308	Cellular Resistance Mechanisms to Targeted Protein Degradation Converge Toward Impairment of the Engaged Ubiquitin Transfer Pathway. <b>2019</b> , 14, 2215-2223	46
307	Development of Small Molecule Chimeras That Recruit AhR E3 Ligase to Target Proteins. <b>2019</b> , 14, 2822-2832	32

306	Inducing the Degradation of Disease-Related Proteins Using Heterobifunctional Molecules. <b>2019</b> , 24,	9
305	Bivalent Ligands for Protein Degradation in Drug Discovery. <b>2019</b> , 17, 160-176	54
304	In Silico Modeling of PROTAC-Mediated Ternary Complexes: Validation and Application. <b>2019</b> , 59, 1634-1644	53
303	SPR-Measured Dissociation Kinetics of PROTAC Ternary Complexes Influence Target Degradation Rate. <b>2019</b> , 14, 361-368	108
302	Emerging modes-of-action in drug discovery. <b>2019</b> , 10, 1550-1568	14
301	Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation. <b>2019</b> , 17, 59	13
300	Targeting Nuclear Receptors with PROTAC degraders. <b>2019</b> , 493, 110452	27
299	Chemoselective Synthesis of Lenalidomide-Based PROTAC Library Using Alkylation Reaction. <b>2019</b> , 21, 3838-3841	25
298	Targeted Protein Internalization and Degradation by ENDosome TArgeting Chimeras (ENDTACs). <b>2019</b> , 5, 1079-1084	19
297	Development of selective small molecule MDM2 degraders based on nutlin. <b>2019</b> , 176, 476-491	26
296	Proteolysis targeting chimeras (PROTACs) in 'beyond rule-of-five' chemical space: Recent progress and future challenges. <b>2019</b> , 29, 1555-1564	127
295	Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation. <b>2019</b> , 174, 159-180	23
294	Molecular design opportunities presented by solvent-exposed regions of target proteins. <b>2019</b> , 39, 2194-2238	16
293	Targeted protein degradation: elements of PROTAC design. <b>2019</b> , 50, 111-119	188
292	AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells. <b>2019</b> , 10, 361	48
291	Targeted Protein Degradation through Cytosolic Delivery of Monobody Binders Using Bacterial Toxins. <b>2019</b> , 14, 916-924	16
290	Development of a Potent Protein Degradator against Oncogenic BCR-ABL Protein. <b>2019</b> , 67, 165-172	9
289	The Novel Mnk1/2 Degradator and Apoptosis Inducer VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis. <b>2019</b> , 11,	9

288	Emerging drug development technologies targeting ubiquitination for cancer therapeutics. <b>2019</b> , 199, 139-154	35
287	Prospects for pharmacological targeting of pseudokinases. <b>2019</b> , 18, 501-526	51
286	A critical evaluation of the approaches to targeted protein degradation for drug discovery. <b>2019</b> , 31, 5-13	27
285	Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. <b>2019</b> , 33, 2685-2694	24
284	Extracellular matrix-mediated regulation of cancer stem cells and chemoresistance. <b>2019</b> , 109, 90-104	36
283	PROTACs suppression of CDK4/6, crucial kinases for cell cycle regulation in cancer. <b>2019</b> , 55, 2704-2707	53
282	PROteolysis TARgeting Chimeras (PROTACs) - Past, present and future. <b>2019</b> , 31, 15-27	263
281	PROTACs: great opportunities for academia and industry. <b>2019</b> , 4, 64	192
280	Disordered region of cereblon is required for efficient degradation by proteolysis-targeting chimera. <b>2019</b> , 9, 19654	11
279	Identification and characterization of cancer vulnerabilities via targeted protein degradation. <b>2019</b> , 31, 81-90	18
278	The PROTAC technology in drug development. <b>2019</b> , 37, 21-30	92
277	Monitoring and deciphering protein degradation pathways inside cells. <b>2019</b> , 31, 61-68	31
276	The BioGRID interaction database: 2019 update. <b>2019</b> , 47, D529-D541	626
275	Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradator of Estrogen Receptor (ER). <b>2019</b> , 62, 1420-1442	106
274	MDM2-Recruiting PROTAC Offers Superior, Synergistic Antiproliferative Activity via Simultaneous Degradation of BRD4 and Stabilization of p53. <b>2019</b> , 79, 251-262	136
273	Peptides meet ubiquitin: Simple interactions regulating complex cell signaling. <b>2019</b> , 111, e24091	3
272	Degradation of proteins by PROTACs and other strategies. <b>2020</b> , 10, 207-238	106
271	Antibody Conjugation of a Chimeric BET Degradator Enables in vivo Activity. <b>2020</b> , 15, 17-25	38

270	Protein degradation through covalent inhibitor-based PROTACs. <b>2020</b> , 56, 1521-1524	44
269	Targeted degradation of anaplastic lymphoma kinase by gold nanoparticle-based multi-headed proteolysis targeting chimeras. <b>2020</b> , 188, 110795	15
268	Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC). <b>2020</b> , 189, 112061	41
267	Discovery of Potent and Selective Epidermal Growth Factor Receptor (EGFR) Bifunctional Small-Molecule Degraders. <b>2020</b> , 63, 1216-1232	51
266	Exploring Targeted Degradation Strategy for Oncogenic KRAS. <i>Cell Chemical Biology</i> , <b>2020</b> , 27, 19-31.e6 8.2	102
265	Covalent Small Molecules as Enabling Platforms for Drug Discovery. <b>2020</b> , 21, 1080-1100	36
264	Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay. <b>2020</b> , 15, 290-295	36
263	Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. <b>2020</b> , 30, 126877	42
262	Targeting STAT3 in Cancer Immunotherapy. <b>2020</b> , 19, 145	101
261	Discovery of a novel EGFR ligand DPBA that degrades EGFR and suppresses EGFR-positive NSCLC growth. <b>2020</b> , 5, 214	8
260	Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs). <b>2020</b> , 207, 112750	5
259	Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK). <b>2020</b> , 63, 14382-14403	25
258	Discovery of First-In-Class Potent and Selective Tropomyosin Receptor Kinase Degraders. <b>2020</b> , 63, 14562-14575	5
257	Design and pharmaceutical applications of proteolysis-targeting chimeric molecules. <b>2020</b> , 182, 114211	5
256	Chemical strategies to overcome resistance against targeted anticancer therapeutics. <b>2020</b> , 16, 817-825	17
255	Inducible Degradation of Target Proteins through a Tractable Affinity-Directed Protein Missile System. <i>Cell Chemical Biology</i> , <b>2020</b> , 27, 1164-1180.e5	8.2 16
254	PROTAC: A promising technology for cancer treatment. <b>2020</b> , 203, 112539	18
253	HaloTag-Targeted Sirtuin-Rearranging Ligand (SirReal) for the Development of Proteolysis-Targeting Chimeras (PROTACs) against the Lysine Deacetylase Sirtuin 2 (Sirt2)*. <b>2020</b> , 21, 3371-3376	5

252	Photoactive Bifunctional Degraders: Precision Tools To Regulate Protein Stability. <b>2020</b> , 63, 15483-15493	7
251	Targeting the Ubiquitin System in Glioblastoma. <b>2020</b> , 10, 574011	10
250	Targeting receptor complexes: a new dimension in drug discovery. <b>2020</b> , 19, 884-901	22
249	An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells. <b>2020</b> , 182, 1009-1026.e37	37
248	Targeting estrogen receptor for degradation with PROTACs: A promising approach to overcome endocrine resistance. <b>2020</b> , 206, 112689	18
247	PROTACs: An Emerging Therapeutic Modality in Precision Medicine. <i>Cell Chemical Biology</i> , <b>2020</b> , 27, 998-1014	92
246	Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets. <b>2020</b> , 17, 583-598	3
245	Targeting Cullin-RING E3 Ligases for Radiosensitization: From NEDDylation Inhibition to PROTACs. <b>2020</b> , 10, 1517	5
244	Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation New Methodologies. <b>2020</b> , 60, 5234-5254	27
243	Discovery of potent small molecule PROTACs targeting mutant EGFR. <b>2020</b> , 208, 112781	20
242	Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry. <b>2020</b> , 11, 4268	45
241	A suite of mathematical solutions to describe ternary complex formation and their application to targeted protein degradation by heterobifunctional ligands. <b>2020</b> , 295, 15280-15291	11
240	Proteolysis targeting chimeras (PROTACs) in cancer therapy. <b>2020</b> , 39, 189	20
239	The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. <b>2020</b> , 10, 10141-10153	20
238	Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. <b>2020</b> , 12,	6
237	Targeted Protein Degradation Phenotypic Studies Using HaloTag CRISPR/Cas9 Endogenous Tagging Coupled with HaloPROTAC3. <b>2020</b> , 91, e81	5
236	Proteolysis-targeting chimeras in breast cancer therapy. <b>2020</b> , 12, 2175-2177	4
235	Targeted degradation of CD147 proteins in melanoma. <b>2020</b> , 105, 104453	4

234	Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs. <b>2020</b> , 142, 11734-11742	58
233	Targeted Degradation of SLC Transporters Reveals Amenability of Multi-Pass Transmembrane Proteins to Ligand-Induced Proteolysis. <i>Cell Chemical Biology</i> , <b>2020</b> , 27, 728-739.e9	8.2 30
232	PROteolysis TARgeting Chimeras (PROTACs) as emerging anticancer therapeutics. <b>2020</b> , 39, 4909-4924	62
231	Scaffold hopping enables direct access to more potent PROTACs with in vivo activity. <b>2020</b> , 56, 6890-6892	9
230	Ibrutinib Resistance Mechanisms and Treatment Strategies for B-Cell lymphomas. <b>2020</b> , 12,	27
229	Targeted protein degradation as a powerful research tool in basic biology and drug target discovery. <b>2020</b> , 27, 605-614	43
228	Fluorophosphonate-Based Degradator Identifies Degradable Serine Hydrolases by Quantitative Proteomics. <b>2020</b> , 21, 2916-2920	2
227	Anticancer strategies by upregulating p53 through inhibition of its ubiquitination by MDM2. <b>2020</b> , 29, 1105-1121	8
226	Mutant-Selective Allosteric EGFR Degradators are Effective Against a Broad Range of Drug-Resistant Mutations. <b>2020</b> , 59, 14481-14489	28
225	The application of ubiquitin ligases in the PROTAC drug design. <b>2020</b> , 52, 776-790	3
224	Mutant-Selective Allosteric EGFR Degradators are Effective Against a Broad Range of Drug-Resistant Mutations. <b>2020</b> , 132, 14589-14597	9
223	The c-MET oncoprotein: Function, mechanisms of degradation and its targeting by novel anti-cancer agents. <b>2020</b> , 1864, 129650	14
222	Proteolysis targeting chimeras (PROTACs) for epigenetics research. <b>2020</b> , 57, 8-16	28
221	Development of Selective Histone Deacetylase 6 (HDAC6) Degradators Recruiting Von Hippel-Lindau (VHL) E3 Ubiquitin Ligase. <b>2020</b> , 11, 575-581	36
220	Critical Assessment of Targeted Protein Degradation as a Research Tool and Pharmacological Modality. <b>2020</b> , 41, 305-317	22
219	Design and synthesis of selective degraders of EGFR mutant. <b>2020</b> , 192, 112199	30
218	Monitoring protein communities and their responses to therapeutics. <b>2020</b> , 19, 414-426	19
217	Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases. <b>2020</b> , 79, 390-405.e7	30



216 PTPs: Degrading the Undruggable. **2020**, 63, 7508-7509

215 Targeted Degradation of Oncogenic KRAS by VHL-Recruiting PROTACs. **2020**, 6, 1367-1375 96

214 A potent KRAS macromolecule degrader specifically targeting tumours with mutant KRAS. **2020**, 11, 3233 28

213 Discovery of the first potent proteolysis targeting chimera (PROTAC) degrader of indoleamine 2,3-dioxygenase 1. **2020**, 10, 1943-1953 19

212 bioPROTACs as versatile modulators of intracellular therapeutic targets including proliferating cell nuclear antigen (PCNA). **2020**, 117, 5791-5800 26

211 Functional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinoma. **2020**, 13, 10

210 Light-induced control of protein destruction by opto-PROTAC. **2020**, 6, eaay5154 66

209 PHOTACs enable optical control of protein degradation. **2020**, 6, eaay5064 98

208 PROTACs: A novel strategy for cancer therapy. **2020**, 67, 171-179 46

207 Hi-JAK-ing the ubiquitin system: The design and physicochemical optimisation of JAK PROTACs. **2020**, 28, 115326 22

206 Proteolysis-Targeting Chimeras as Therapeutics and Tools for Biological Discovery. **2020**, 181, 102-114 277

205 Harnessing the Power of Proteolysis for Targeted Protein Inactivation. **2020**, 77, 446-460 80

204 A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. **2020**, 99, 103811 83

203 Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy. **2020**, 3, 1900210 1

202 Discovery and biological evaluation of proteolysis targeting chimeras (PROTACs) as an EGFR degraders based on osimertinib and lenalidomide. **2020**, 30, 127167 12

201 Small-molecule PROTACs: novel agents for cancer therapy. **2020**, 12, 915-938 7

200 PROTACs to address the challenges facing small molecule inhibitors. **2021**, 210, 112993 20

199 Hybrid Quinazoline 1,3,5-Triazines as Epidermal Growth Factor Receptor (EGFR) Inhibitors with Anticancer Activity: Design, Synthesis, and Computational Study. **2021**, 16, 822-838 2

198	Challenges and Opportunities in Cancer Drug Resistance. <b>2021</b> , 121, 3297-3351	66
197	The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance. <b>2021</b> , 218, 107677	3
196	CDK Family PROTAC Profiling Reveals Distinct Kinetic Responses and Cell Cycle-Dependent Degradation of CDK2. <b>2021</b> , 26, 560-569	7
195	The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. <b>2021</b> , 40, 564-577	3
194	Proteolysis targeting chimera (PROTAC) for epidermal growth factor receptor enhances anti-tumor immunity in non-small cell lung cancer. <b>2021</b> , 82, 422-429	4
193	The future of covalent inhibition. <b>2021</b> , 56, 267-284	
192	Proteolysis targeting chimera (PROTAC) in drug discovery paradigm: Recent progress and future challenges. <b>2021</b> , 210, 112981	35
191	PROTACs and Building Blocks: The 2D Chemical Space in Very Early Drug Discovery. <b>2021</b> , 26,	10
190	Major advances in targeted protein degradation: PROTACs, LYTACs, and MADTACs. <b>2021</b> , 296, 100647	26
189	Photocontrollable PROTAC molecules: Structure and mechanism of action. <b>2021</b> , 71, 161-176	
188	Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells. <b>2021</b> , 2365, 151-171	2
187	MST and TRIC Technology to Reliably Study PROTAC Binary and Ternary Binding in Drug Development. <b>2021</b> , 2365, 115-133	0
186	PROTACs, molecular glues and bifunctionals from bench to bedside: Unlocking the clinical potential of catalytic drugs. <b>2021</b> , 60, 67-190	6
185	Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1. <b>2021</b> , 143, 593-598	52
184	High-Throughput Quantitative Assay Technologies for Accelerating the Discovery and Optimization of Targeted Protein Degradation Therapeutics. <b>2021</b> , 26, 503-517	6
183	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degradators of Oncoproteins. <b>2021</b> , 34, 108532	15
182	[Induced degradation of proteins by PROTACs and other strategies: towards promising drugs]. <b>2021</b> , 215, 25-43	0
181	Exploiting Ubiquitin Ligases for Induced Target Degradation as an Antiviral Strategy. <b>2021</b> , 1322, 339-357	0

180	Mutant-selective degradation by BRAF-targeting PROTACs. <b>2021</b> , 12, 920	28
179	Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta. <b>2021</b> , 61, 1368-1382	22
178	Allosteric Inhibition of the Epidermal Growth Factor Receptor. <b>2021</b> , 60, 500-512	1
177	From Degraders to Molecular Glues: New Ways of Breaking Down Disease-Associated Proteins. <b>2021</b> , 47-85	1
176	The Hydroxyquinoline Analogue YUM70 Inhibits GRP78 to Induce ER Stress-Mediated Apoptosis in Pancreatic Cancer. <b>2021</b> , 81, 1883-1895	14
175	Musashi-2 (MSI2) regulates epidermal growth factor receptor (EGFR) expression and response to EGFR inhibitors in EGFR-mutated non-small cell lung cancer (NSCLC). <b>2021</b> , 10, 29	3
174	Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class. <b>2021</b> , 22, 2011-2031	4
173	The Role of the Ubiquitin Proteasome System in Glioma: Analysis Emphasizing the Main Molecular Players and Therapeutic Strategies Identified in Glioblastoma Multiforme. <b>2021</b> , 58, 3252-3269	4
172	Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery. <b>2021</b> , 9, 639176	4
171	Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer. <b>2021</b> , 14, 301-317	5
170	Signaling Pathways in Cancer: Therapeutic Targets, Combinatorial Treatments, and New Developments. <b>2021</b> , 10,	13
169	From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation. <b>2021</b> , 9, 672267	12
168	Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors. <b>2021</b> , 13,	10
167	EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. <b>2021</b> , 167, 105583	15
166	Advances in targeting 'undruggable' transcription factors with small molecules. <b>2021</b> , 20, 669-688	28
165	Cancer Selective Target Degradation by Folate-Caged PROTACs. <b>2021</b> , 143, 7380-7387	26
164	Selective and noncovalent targeting of RAS mutants for inhibition and degradation. <b>2021</b> , 12, 2656	16
163	Expression and purification of functional recombinant CUL2BBX1 from E. coli. <b>2021</b> , 11, 11224	2

162	Advancing targeted protein degradation for cancer therapy. <b>2021</b> , 21, 638-654		52
161	Effective degradation of EGFR mutant proteins by CRBN-based PROTACs through both proteasome and autophagy/lysosome degradation systems. <b>2021</b> , 218, 113328		17
160	Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. <b>2021</b> , 40, 4079-4093		16
159	Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies. <b>2021</b> , 41, e286-e293		1
158	Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis-targeting chimeras. <b>2021</b> , 2, 341-350		14
157	Discovery of a Brigatinib Degradable SIAIS164018 with Destroying Metastasis-Related Oncoproteins and a Reshuffling Kinome Profile. <b>2021</b> , 64, 9152-9165		5
156	The rise of covalent proteolysis targeting chimeras. <b>2021</b> , 62, 24-33		16
155	Targeting Protein Kinases Degradation by PROTACs. <b>2021</b> , 9, 679120		10
154	Expanding the arsenal of E3 ubiquitin ligases for proximity-induced protein degradation. <i>Cell Chemical Biology</i> , <b>2021</b> , 28, 1014-1031	8.2	8
153	Light-Controllable PROTACs for Temporospacial Control of Protein Degradation. <b>2021</b> , 9, 678077		6
152	The PROTACTable genome. <b>2021</b> , 20, 789-797		20
151	Targeted protein degradation: A promise for undruggable proteins. <i>Cell Chemical Biology</i> , <b>2021</b> , 28, 934-951		27
150	Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. <b>2021</b> ,		5
149	Reversible Covalent PROTACs: Novel and Efficient Targeted Degradation Strategy. <b>2021</b> , 9, 691093		1
148	Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway. <i>Cell Chemical Biology</i> , <b>2021</b> , 28, 1072-1080	8.2	12
147	Targeted Protein Degradation: The New Frontier of Antimicrobial Discovery?. <b>2021</b> , 7, 2050-2067		4
146	Targeting the CDK6 Dependence of Ph+ Acute Lymphoblastic Leukemia. <b>2021</b> , 12,		1
145	Preclinical Studies of PROTACs in Hematological Malignancies. <b>2021</b> , 21, 7-22		1

144	Destruction of DNA-Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG. <b>2021</b> , 8, e2102555	15
143	Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. <b>2021</b> ,	12
142	Machine learning modeling of protein-intrinsic features predicts tractability of targeted protein degradation.	1
141	Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation. <b>2021</b> , 223, 113645	10
140	Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation. <b>2021</b> , 2, 725-742	30
139	Enhancing Intracellular Accumulation and Target Engagement of PROTACs with Reversible Covalent Chemistry.	2
138	Rationalizing PROTAC-mediated ternary complex formation using Rosetta.	5
137	Improved Accuracy for Modeling PROTAC-Mediated Ternary Complex Formation and Targeted Protein Degradation via New In Silico Methodologies.	1
136	Mutant-selective Degradation by BRAF-targeting PROTACs.	1
135	SPR-measured dissociation kinetics of PROTAC ternary complexes influence target degradation rate.	2
134	Chemically Induced Cellular Proteolysis: An Emerging Therapeutic Strategy for Undruggable Targets. <b>2018</b> , 41, 933-942	19
133	Targeting Epidermal Growth Factor Receptor in Non-Small-Cell-Lung Cancer: Current State and Future Perspective. <b>2019</b> , 19, 984-991	8
132	Targeting Degradation of EGFR through the Allosteric Site Leads to Cancer Cell Detachment-Promoted Death. <b>2019</b> , 11,	8
131	Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors. <b>2020</b> , 1, 131-152	9
130	Current strategies for the design of PROTAC linkers: a critical review. <b>2020</b> , 1,	34
129	Photopharmacology-based small-molecule proteolysis targeting chimeras: optical control of protein degradation. <b>2020</b> , 12, 1991-1993	2
128	Trivalent PROTACs enhance protein degradation via combined avidity and cooperativity. <b>2021</b> , 17, 1157-1167	14
127	The Novel Mnk1/2 Degradator VNLG-152 Potently Inhibits TNBC Tumor Growth and Metastasis.	

126	bioPROTACs as versatile modulators of intracellular therapeutic targets: Application to proliferating cell nuclear antigen (PCNA).	
125	Chapter 1:PROTAC-mediated Target Degradation: A Paradigm Changer in Drug Discovery?. <b>2020</b> , 1-13	1
124	Preclinical and Clinical Advances of Targeted Protein Degradation as a Novel Cancer Therapeutic Strategy: An Oncologist Perspective. <b>2021</b> , 16, 1-12	1
123	Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor. <b>2022</b> , 227, 113922	3
122	VHL-based PROTACs as potential therapeutic agents: Recent progress and perspectives. <b>2022</b> , 227, 113906	6
121	An activity-guided map of electrophile-cysteine interactions in primary human immune cells.	
120	CHAPTER 7:Targeted Protein Degradation Chemical Probes. <b>2020</b> , 150-181	
119	Regulation of Mitogen-Activated Protein Kinase Signaling Pathways by the Ubiquitin-Proteasome System and Its Pharmacological Potential. <b>2021</b> , 73, 263-296	1
118	Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase. <b>2021</b> , 13,	2
117	Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?. <b>2021</b> , 169, 103532	0
116	Potential application of proteolysis targeting chimera (PROTAC) modification technology in natural products for their targeted protein degradation. <b>2022</b> , 11, 199-207	1
115	KRAS mutation: from undruggable to druggable in cancer. <b>2021</b> , 6, 386	22
114	Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC).. <b>2021</b> , 119, 105508	3
113	Targeted protein degradation at the host-pathogen interface. <b>2021</b> ,	1
112	Receptor Tyrosine Kinases. <b>2021</b> ,	0
111	Impact of PROTAC Linker Plasticity on the Solution Conformations and Dissociation of the Ternary Complex.. <b>2022</b> , 62, 340-349	4
110	The Renaissance of Cyclin Dependent Kinase Inhibitors.. <b>2022</b> , 14,	6
109	Target Protein Localisation and Its Impact on PROTAC-Mediated Degradation.	0

108	Strategies for designing proteolysis targeting chimaeras (PROTACs).. <b>2022,</b>	4
107	Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programmed cell death.	
106	PROTAC targeted protein degraders: the past is prologue.. <b>2022,</b>	91
105	Targeting Histone Deacetylases: Opportunities for Cancer Treatment and Chemoprevention.. <b>2022,</b> 14,	3
104	.. <b>2022,</b>	2
103	Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles.. <b>2021,</b> 9, 805336	1
102	Discovery of novel potent covalent inhibitor-based EGFR degrader with excellent in vivo efficacy.. <b>2022,</b> 120, 105605	1
101	Susceptibility of Lung Carcinoma Cells to Nanostructured Lipid Carrier of ARV-825, a BRD4 Degrading Proteolysis Targeting Chimera.. <b>2022,</b> 1	3
100	A highly accurate metadynamics-based Dissociation Free Energy method to calculate protein-protein and protein-ligand binding potencies.. <b>2022,</b> 12, 2024	0
99	Ligands with different dimeric configurations potently activate the EphA2 receptor and reveal its potential for biased signaling.. <b>2022,</b> 25, 103870	0
98	Protein Degradation Technology. <b>2022,</b> 10, 21-26	
97	Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?. <b>2022,</b> 10, 854352	1
96	Combination of artesunate and WNT974 induces KRAS protein degradation by upregulating E3 ligase ANACP2 and ETRCP in the ubiquitin-proteasome pathway.. <b>2022,</b> 20, 34	1
95	Profiling of diverse tumor types establishes the broad utility of VHL-based ProTACs and triages candidate ubiquitin ligases.. <b>2022,</b> 25, 103985	3
94	Discovery of Potent PROTACs Targeting EGFR Mutants through the Optimization of Covalent EGFR Ligands.. <b>2022,</b>	4
93	Roles of Cullin-RING Ubiquitin Ligases in Cardiovascular Diseases.. <b>2022,</b> 12,	0
92	Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers.. <b>2022,</b> 13, 839857	1
91	Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis.. <b>2022,</b> 234, 114253	1

90	Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth.. <b>2022</b> , 106209	0
89	Proteolysis-targeting chimeras (PROTACs) in cancer therapy.. <b>2022</b> , 21, 99	4
88	An anti-influenza A virus microbial metabolite acts by degrading viral endonuclease PA.. <b>2022</b> , 13, 2079	0
87	Signaling Pathway and Small-Molecule Drug Discovery of FGFR: A Comprehensive Review.. <b>2022</b> , 10, 860985	3
86	Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy.. <b>2022</b> ,	4
85	Discovery of Highly Potent and Selective CRBN-Recruiting EGFR <sup>&L858r/T790M&/sup> Degraders <i>in Vivo</i>.	
84	Overcoming Cancer Drug Resistance Utilizing PROTAC Technology.. <b>2022</b> , 10, 872729	0
83	Design and synthesis of proteolysis targeting chimeras (PROTACs) as an EGFR degrader based on CO-1686. <b>2022</b> , 114455	1
82	Molecular glues: enhanced protein-protein interactions and cell proteome editing. 1	0
81	Novel GSK-3 kinase inhibitor Pym-5 induces GSK-3 $\beta$ rather than GSK-3 $\alpha$ dependent melanogenesis in murine melanoma cells. <b>2022</b> ,	
80	Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.. <b>2022</b> , 215716	2
79	Recent advances in IAP-based PROTACs (SNIPERs) as potential therapeutic agents.. <b>2022</b> , 37, 1437-1453	2
78	A general strategy for the design and evaluation of heterobifunctional tools: applications to protein localization and phase separation.	
77	Design of a mucin-selective protease for targeted degradation of cancer-associated mucins.	1
76	PROTACs: past, present and future. <b>2022</b> , 51, 5214-5236	16
75	RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. <b>2022</b> , 13,	1
74	Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. <b>2022</b> , 65, 8416-8443	2
73	Azobenzene Photoswitches in Proteolysis Targeting Chimeras: Photochemical Control Strategies and Therapeutic Benefits. <b>2022</b> , 7,	0



72	Major Advances in Emerging Degradation Technologies. 10,	0
71	Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degradation of Enhancer of Zeste Homolog 2.	1
70	Proteolysis-targeting chimeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. <b>2022</b> , 37, 1667-1693	1
69	Discovery of highly potent and selective CRBN-recruiting EGFR <sup>L858R/T790M</sup> degraders in vivo. <b>2022</b> , 238, 114509	1
68	Recent advances in the development of EGFR degraders: PROTACs and LYTACs. <b>2022</b> , 239, 114533	2
67	The importance of cellular degradation kinetics for understanding mechanisms in targeted protein degradation. <b>2022</b> , 51, 6210-6221	0
66	Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation. <b>2022</b> , 65, 8798-8827	2
65	Targeting micro-environmental pathways by PROTACs as a therapeutic strategy. <b>2022</b> ,	2
64	Synthesis and biological evaluation of a tumor-selective degrader of PARP1. <b>2022</b> , 69, 116908	0
63	Molecular Glues: The Adhesive Connecting Targeted Protein Degradation to the Clinic.	0
62	Current updates on EGFR and HER2 tyrosine kinase inhibitors for the breast cancer. <b>2022</b> , 31, 1401-1413	
61	Key Considerations in Targeted Protein Degradation Drug Discovery and Development. 10,	1
60	Novel Design Strategies to Enhance the Efficiency of Proteolysis Targeting Chimeras.	0
59	Next-generation Bruton's tyrosine kinase (BTK) inhibitors potentially targeting BTK C481S mutation- Recent developments and Perspectives.. <b>2022</b> , 22,	2
58	Recent developments in the Medicinal Chemistry and therapeutic potential of anti-cancer PROTAC based molecules. <b>2022</b> , 29,	
57	Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers. <b>2022</b> , 14, 4103	1
56	Accelerating PROTAC drug discovery: Establishing a relationship between ubiquitination and target protein degradation. <b>2022</b> , 628, 68-75	1
55	Proteolysis-targeting chimeras (PROTACs) as novel biotechnology for cancer therapy. <b>2022</b> , 71-88	0

54	Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders. <b>2022</b> , 51, 8216-8257	5
53	Can EGFR be a therapeutic target in breast cancer?. <b>2022</b> , 1877, 188789	1
52	Accelerated rational PROTAC design via deep learning and molecular simulations. <b>2022</b> , 4, 739-748	2
51	Target protein localization and its impact on PROTAC-mediated degradation. <b>2022</b> ,	1
50	Exploring the target scope of KEAP1 E3 ligase-based PROTACs. <b>2022</b> ,	3
49	Light-Activating PROTACs in Cancer: Chemical Design, Challenges, and Applications. <b>2022</b> , 12, 9674	0
48	Recent Advances of Degradation Technologies Based on PROTAC Mechanism. <b>2022</b> , 12, 1257	0
47	Proteolysis Targeting Chimeras (PROTACs): A Perspective on Integral Membrane Protein Degradation.	2
46	Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1. <b>2022</b> , 114830	1
45	Recent Advances in PROTAC Technology Toward New Therapeutic Modalities.	0
44	Applications of covalent chemistry in targeted protein degradation.	2
43	Current strategies for improving limitations of proteolysis targeting chimeras. <b>2022</b> , 107927	0
42	Manipulating Autophagic Degradation in Human Diseases: from Mechanisms to Interventions.	0
41	PROTAC Degradation of Estrogen Receptor $\alpha$ Targeting DNA-Binding Domain in Breast Cancer.	2
40	Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models.	0
39	PROTAC: A Novel drug delivery technology for targeting proteins in cancer cells. <b>2022</b> , 20,	0
38	Targeted degradation of PCNA outperforms stoichiometric inhibition to result in programmed cell death. <b>2022</b> ,	0
37	PROTACs in Gastrointestinal Cancers. <b>2022</b> ,	1

36	A bibliometric analysis of PROTAC from 2001 to 2021. <b>2022</b> , 244, 114838	1
35	Targeted Protein Degradation in Antiviral Drug Discovery. <b>2022</b> , 465-490	0
34	The importance of controls in targeted protein degradation: Determining mechanism. <b>2022</b> ,	0
33	PROTACS: A technology with a gold rush-like atmosphere. <b>2023</b> , 247, 115037	0
32	Synthesis of SNIPERs against BCR-ABL with kinase inhibitors and a method to evaluate their growth inhibitory activity derived from BCR-ABL degradation. <b>2022</b> ,	0
31	PROTAC: targeted drug strategy. Principles and limitations. <b>2022</b> , 71, 2310-2334	0
30	PROTAC therapy as a new targeted therapy for lung cancer. <b>2022</b> ,	0
29	Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery.	0
28	Machine Learning Modeling of Protein-intrinsic Features Predicts Tractability of Targeted Protein Degradation. <b>2022</b> ,	0
27	An overview of PROTACs: a promising drug discovery paradigm. <b>2022</b> , 3,	0
26	Advancing targeted protein degradation for metabolic diseases therapy. <b>2022</b> , 106627	0
25	Targeted protein degradation as an antiviral approach. <b>2022</b> , 105480	0
24	Emerging TACnology: Heterobifunctional Small Molecule Inducers of Targeted Posttranslational Protein Modifications. <b>2023</b> , 28, 690	0
23	Progress of small molecules for targeted protein degradation: PROTACs and other technologies.	1
22	Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.	0
21	Targeted Degradation of PD-L1 and Activation of the STING Pathway by Carbon-Dot-Based PROTACs for Cancer Immunotherapy.	0
20	Building bioorthogonal click-release capable artificial receptors on cancer cell surface for imaging, drug targeting and delivery. <b>2022</b> ,	0
19	Discovery of novel exceptionally potent and orally active c-MET PROTACs for the treatment of tumors with MET alterations. <b>2023</b> ,	0

- 18 Targeted Biomolecule Regulation Platform: A Split-and-Mix PROTAC Approach. **2023**, 145, 7879-7887 ○
- 17 Targeted protein degradation in cancers: Orthodox PROTACs and beyond. **2023**, 4, 100413 ○
- 16 Crizotinib-based proteolysis targeting chimera suppresses gastric cancer by promoting MET degradation. ○
- 15 Recent Advances in PROTAC-Based Antiviral Strategies. **2023**, 11, 270 ○
- 14 Ternary complex dissociation kinetics contribute to mutant-selective EGFR degradation. **2023**, 30, 175-187.e15○
- 13 Advancing Strategies for Proteolysis-Targeting Chimera Design. **2023**, 66, 2308-2329 ○
- 12 Recent advances in targeted protein degraders as potential therapeutic agents. 1
- 11 Rare molecular subtypes of lung cancer. **2023**, 20, 229-249 ○
- 10 Targeting the Epidermal Growth Factor Receptor with Molecular Degraders: State-of-the-Art and Future Opportunities. **2023**, 66, 3135-3172 ○
- 9 Elucidation of Genome-wide Understudied Proteins targeted by PROTAC-induced degradation using Interpretable Machine Learning. ○
- 8 The roles of E3 ubiquitin ligases in cancer progression and targeted therapy. **2023**, 13, ○
- 7 Targeting androgen receptor and the variants by an orally bioavailable Proteolysis Targeting Chimeras compound in castration resistant prostate cancer. **2023**, 90, 104500 ○
- 6 The application of targeted protein degradation technologies to G protein-coupled receptors. ○
- 5 Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy. ○
- 4 Small Molecule Degraders of Protein Tyrosine Phosphatase 1B and T-Cell Protein Tyrosine Phosphatase for Cancer Immunotherapy. ○
- 3 PROTACing oncoproteins: targeted protein degradation for cancer therapy. **2023**, 22, ○
- 2 Structure-activity relationship study of RSL3-based GPX4 degraders and its potential noncovalent optimization. **2023**, 115393 ○
- 1 Proteolysis targeting chimeras in non-small cell lung cancer. **2023**, 117, 102561 ○

